M Raderer1, B Streubel, S Wöhrer, M Häfner, A Chott. 1. Department of Medicine I, Division of Oncology, Medical University Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria. markus.raderer@meduniwien.ac.at
Abstract
BACKGROUND AND AIMS: The role of antibiotic treatment in early stage gastric mucosa associated lymphoid tissue (MALT) lymphoma not associated with Helicobacter pylori infection has not been investigated. PATIENTS AND METHODS: Six patients with localised gastric MALT lymphoma underwent antibiotic treatment with clarithromycin, metronidazole, and pantoprazole. Staging, including endosonography plus gastroscopy, computed tomography of the thorax and abdomen, colonoscopy, magnetic resonance imaging of the salivary glands, and bone marrow biopsy were performed to rule out distant spread of the disease. In addition, MALT specific genetic changes, including reverse transcriptase-polymerase chain reaction for t(11;18)(q21;q21), were tested in all patients. H pylori infection was ruled out by histology, urease breath test, serology, and stool antigen testing. RESULTS: All six patients had MALT lymphoma restricted to the stomach, and no evidence of infection with H pylori was found. Only one patient tested positive for t(11;18)(q21;q21) while the remaining five displayed no genetic aberrations. Following antibiotic treatment, endoscopic controls were performed every three months. Five patients responded with lymphoma regression between three and nine months following antibiotic treatment (one partial remission and four complete responses). One patient had stable disease for 12 months and was then referred for chemotherapy. CONCLUSIONS: Patients with early stage gastric MALT lymphoma negative for H pylori might still benefit from antibiotic treatment as the sole treatment modality.
BACKGROUND AND AIMS: The role of antibiotic treatment in early stage gastric mucosa associated lymphoid tissue (MALT) lymphoma not associated with Helicobacter pylori infection has not been investigated. PATIENTS AND METHODS: Six patients with localised gastric MALT lymphoma underwent antibiotic treatment with clarithromycin, metronidazole, and pantoprazole. Staging, including endosonography plus gastroscopy, computed tomography of the thorax and abdomen, colonoscopy, magnetic resonance imaging of the salivary glands, and bone marrow biopsy were performed to rule out distant spread of the disease. In addition, MALT specific genetic changes, including reverse transcriptase-polymerase chain reaction for t(11;18)(q21;q21), were tested in all patients. H pylori infection was ruled out by histology, urease breath test, serology, and stool antigen testing. RESULTS: All six patients had MALT lymphoma restricted to the stomach, and no evidence of infection with H pylori was found. Only one patient tested positive for t(11;18)(q21;q21) while the remaining five displayed no genetic aberrations. Following antibiotic treatment, endoscopic controls were performed every three months. Five patients responded with lymphoma regression between three and nine months following antibiotic treatment (one partial remission and four complete responses). One patient had stable disease for 12 months and was then referred for chemotherapy. CONCLUSIONS:Patients with early stage gastric MALT lymphoma negative for H pylori might still benefit from antibiotic treatment as the sole treatment modality.
Authors: M Raderer; C Osterreicher; K Machold; M Formanek; W Fiebiger; M Penz; B Dragosics; A Chott Journal: Ann Oncol Date: 2001-07 Impact factor: 32.976
Authors: Hongxiang Liu; Hongtao Ye; Agnes Ruskone-Fourmestraux; Daphne De Jong; Stefano Pileri; Christian Thiede; Anne Lavergne; Henk Boot; Giancarlo Caletti; Thomas Wündisch; Thierry Molina; Babs G Taal; Sabattini Elena; Togliani Thomas; Pier Luigi Zinzani; Andreas Neubauer; Manfred Stolte; Rifat A Hamoudi; Ahmet Dogan; Peter G Isaacson; Ming-Qing Du Journal: Gastroenterology Date: 2002-05 Impact factor: 22.682
Authors: H Liu; A Ruskon-Fourmestraux; A Lavergne-Slove; H Ye; T Molina; Y Bouhnik; R A Hamoudi; T C Diss; A Dogan; F Megraud; J C Rambaud; M Q Du; P G Isaacson Journal: Lancet Date: 2001-01-06 Impact factor: 79.321
Authors: H Nakase; K Okazaki; M Ohana; K Ikeda; K Uchida; S Uose; T Itoh; M Iwano; N Watanabe; S Yazumi; C Kawanami; F Inoue; T Chiba Journal: Endoscopy Date: 2002-04 Impact factor: 10.093
Authors: B Streubel; I Simonitsch-Klupp; L Müllauer; A Lamprecht; D Huber; R Siebert; M Stolte; F Trautinger; J Lukas; A Püspök; M Formanek; T Assanasen; H-K Müller-Hermelink; L Cerroni; M Raderer; A Chott Journal: Leukemia Date: 2004-10 Impact factor: 11.528
Authors: Marc Lecuit; Eric Abachin; Antoine Martin; Claire Poyart; Philippe Pochart; Felipe Suarez; Djaouida Bengoufa; Jean Feuillard; Anne Lavergne; Jeffrey I Gordon; Patrick Berche; Loïc Guillevin; Olivier Lortholary Journal: N Engl J Med Date: 2004-01-15 Impact factor: 91.245
Authors: Hongtao Ye; Hongxiang Liu; Markus Raderer; Andreas Chott; Agnes Ruskone-Fourmestraux; Andrew Wotherspoon; Martin J S Dyer; Shih-Sung Chuang; Ahmet Dogan; Peter G Isaacson; Ming-Qing Du Journal: Blood Date: 2002-11-27 Impact factor: 22.113
Authors: Erin C Bridgeford; Robert P Marini; Yan Feng; Nicola M A Parry; Barry Rickman; James G Fox Journal: Vet Immunol Immunopathol Date: 2008-01-19 Impact factor: 2.046
Authors: Sang-Won Kim; Do Hoon Lim; Yong Chan Ahn; Won Seog Kim; Seok Jin Kim; Young Hyeh Ko; Kyoung-Mee Kim Journal: World J Gastroenterol Date: 2013-09-28 Impact factor: 5.742